Search results for "mortality [Cerebellar Neoplasms]"

showing 10 items of 472 documents

Cancer cure for 32 cancer types: results from the EUROCARE-5 study

2020

Abstract Background Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. Methods 7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15–74 years in 1990–2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95…

OncologyAdultMalemedicine.medical_specialtySkin NeoplasmsAdolescentEpidemiologyPopulation03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerLife ExpectancyProstateInternal medicineNeoplasmsmedicineHumans030212 general & internal medicineRegistrieseducationThyroid cancerMelanomaComputingMilieux_MISCELLANEOUSAgededucation.field_of_study[SHS.SOCIO]Humanities and Social Sciences/SociologyRelative survivalbusiness.industryMelanomaMortality rateCancerGeneral MedicineMiddle Agedmedicine.disease3. Good healthEuropeSurvival Ratemedicine.anatomical_structure030220 oncology & carcinogenesisQuality of LifeFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness
researchProduct

Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series.

2012

e11056 Background: Breast cancer (BC) is frequent in the elderly and is burdened by high recurrence and death rates, due mostly to undertreatment. Trastuzumab (T), in combination with chemotherapy (CT) or hormonotherapy (HT), is a well-established treatment strategy for early and advanced HER2-positive (HER2+) breast cancer, but has been poorly studied in the elderly setting due to its infrequency. The aim of our study is to assess the safety of T in elderly patients with HER2+ BC. Methods: Between 2005 and 2010, consecutive HER2+ breast cancer patients of ≥70 years of age referred to two oncology centers and that received T-based therapy were retrospectively reviewed. All patients were tr…

OncologyCancer ResearchSeries (stratigraphy)medicine.medical_specialtyChemotherapyEjection fractionbusiness.industryMortality ratemedicine.medical_treatmentGeriatric assessmentmedicine.diseaseBreast cancerOncologyTrastuzumabInternal medicineHER2 Positive Breast CancerMedicinebusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-…

2016

Objectives: To investigate cancer-specific mortality and other-cause mortality in prostate cancer patients with nodal metastases. Methods: The study included 411 patients treated with radical prostatectomy and pelvic lymph node dissection for prostate cancer with lymph node metastases at 10 tertiary care centers between 1995 and 2014. Kaplan–Meier analyses were used to assess cancer-specific mortality-free survival rates at 8 years' follow up in the overall population, and after stratifying patients according to clinical and pathological parameters. Uni- and multivariable competing risk Cox regression analyses were used to assess cancer-specific mortality and other-cause mortality. Finally,…

OncologyMalemedicine.medical_treatment030232 urology & nephrologyProstate cancer0302 clinical medicineRobotic Surgical ProceduresLymph nodeeducation.field_of_studyProstatectomyMortality rateLymph NodePrognosiscancer-specific mortality competing risk analysis lymph node metastases other-cause mortality radical prostatectomylymph node metastaseDissectionmedicine.anatomical_structure030220 oncology & carcinogenesisLymphatic MetastasisLymphSurvival Analysicancer-specific mortality; competing risk analysis; lymph node metastases; other-cause mortality; radical prostatectomycancer-specific mortality; competing risk analysis; lymph node metastases; other-cause mortality; radical prostatectomy; Urologyother-cause mortalityHumanlymph node metastasesRiskmedicine.medical_specialtyRobotic Surgical ProcedurePrognosiUrologyPopulationUrologycancer-specific mortality03 medical and health sciencesInternal medicinemedicineHumanseducationcompeting risk analysiProstatectomybusiness.industryProportional hazards modelcompeting risk analysisProstatic NeoplasmsLymphatic MetastasiProstate-Specific Antigenmedicine.diseaseSurvival Analysisradical prostatectomyProstatic NeoplasmLymph Node ExcisionLaparoscopyLymph Nodesbusiness
researchProduct

NUPR1 works against the metabolic stress-induced autophagy-associated cell death in pancreatic cancer cells.

2013

The incidence of pancreatic adenocarcinoma is increasing with more than 43,000 predicted new cases in the US and 65,000 in Europe this year. Pancreatic cancer patients have a short life expectancy with less than 3–4% 5-y survival, which results in an equivalent incidence and mortality rate. One of the major challenges in pancreatic cancer is the identification of pharmacological approaches that overcome the resistance of this cancer to therapy. Intensive research in the past decades has led to the classification of pancreatic cancers and the identification of the driver key genetic events. Despite the advances in understanding the molecular mechanisms responsible for pancreatic cancer patho…

Oncologymedicine.medical_specialtyCell SurvivalDrug resistanceDiseaseBiologyProtein Serine-Threonine KinasesModels BiologicalAurora KinasesStress PhysiologicalPancreatic cancerInternal medicineCarcinomamedicineAutophagyBasic Helix-Loop-Helix Transcription FactorsHumansMolecular BiologyCell DeathMechanism (biology)Mortality rateCancerCell Biologymedicine.diseaseAutophagic PunctumNeoplasm ProteinsEndocrinologyDrug Resistance NeoplasmAdenocarcinomaCarcinoma Pancreatic DuctalAutophagy
researchProduct

Programmed colorectal cancer screening decreases incidence and mortality

2019

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer- related deaths in the world (1). Detecting and removing precancerous lesions or detecting tumors in early stages through endoscopy decreases CRC mortality (2). Randomized controlled trials (RCTs) have shown that CRC screening based on guaiac fecal occult blood testing (gFOBT) and flexible sigmoidoscopy is effective in reducing incidence and mortality rates of CRC (3).

Oncologymedicine.medical_specialtyColorectal cancerlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineMedicine030212 general & internal medicineneoplasmsHepatologymedicine.diagnostic_testbusiness.industryMortality rateIncidence (epidemiology)Fecal occult bloodGastroenterologyCancerSigmoidoscopymedicine.diseasedigestive system diseasesEndoscopy030220 oncology & carcinogenesisbusinessTranslational Gastroenterology and Hepatology
researchProduct

Risk of pancreatic malignancy and mortality in branch-duct IPMNs undergoing surveillance: A systematic review and meta-analysis

2016

Abstract Background Safety of non-operative management for low-risk branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) is debated. Aim To perform a systematic review/meta-analysis to determine their risk of developing pancreatic malignancy and of pancreatic malignancy-related deaths. Methods A MEDLINE search was performed and methodology was based on PRISMA statement. Incidence rates of overall pancreatic malignancy, malignant BD-IPMN, IPMN-distinct PDAC, and of pancreatic malignancy-related death rates were calculated by dividing the total number of events by the total number of person-years (pyrs) of follow-up. Heterogeneity was determined by I2 statistic. Results 20 studies …

Oncologymedicine.medical_specialtyPancreatic malignancyendocrine system diseasesmedicine.medical_treatmentNon-operative managementGastroenterologyMalignant transformation03 medical and health sciencesPancreatectomy0302 clinical medicineRisk FactorsInternal medicinePancreatic cancermedicineHumansWatchful WaitingHepatologybusiness.industryFollow-upMortality ratePancreatic DuctsGastroenterologyPancreatic cancermedicine.diseasePancreatic NeoplasmsCell Transformation Neoplastic030220 oncology & carcinogenesisMeta-analysisPancreatectomyVery low risk030211 gastroenterology & hepatologyfollow-up; non-operative management; pancreatectomy; pancreatic cancerNeoplasms Cystic Mucinous and SerousbusinessWatchful waitingCarcinoma Pancreatic DuctalDigestive and Liver Disease
researchProduct

Second follow-up of a German cohort on childhood cancer incidence after exposure to postnatal diagnostic x-ray.

2019

Studies on children exposed to ionizing radiation by computed tomography (CT) indicate an increased risk of leukemia and central nervous system (CNS) tumors. Evidence of the risks associated with diagnostic X-ray examinations, the most frequent examination in pediatric radiology, in which the radiation dose is up to 750 times lower compared to CT examinations, is less clear.a#13; This study presents results of the second follow-up for the risk of childhood cancer in a cohort of children (alt;15 years) with diagnostic X-ray exposure at a large German hospital during 1976-2003 followed for additional 10 years until 2016.a#13; With a latency period of six months, 92,998 children contributed 79…

Oncologymedicine.medical_specialtybusiness.industryIncidence (epidemiology)Public Health Environmental and Occupational HealthCancerContext (language use)General MedicineChildhood Cancer ; Cohort Study ; Diagnostic X-ray ; Low Dose Radiationmedicine.diseaseLeukemiaStandardized mortality ratioLatency stageInternal medicineCohortmedicinebusinessWaste Management and DisposalThyroid cancer
researchProduct

Melanoma epidemiology, prognosis and trends in Latvia

2012

Background Melanoma incidence and mortality rates are increasing worldwide within the white population. Clinical and histological factors have been usually used for the prognosis and assessment of the risk for melanoma. Objectives The aim of the study was to describe the clinical and histopathological features of the cutaneous melanoma (CM) in the Latvian population, to test the association between melanoma features and patient survival, and to assess the time trends for melanoma incidence. Methods We undertook a descriptive, retrospective analysis of archive data of 984 melanoma patients treated at the largest oncological hospital of Latvia, Riga East University Hospital Latvian Oncology C…

Oncologymedicine.medical_specialtyeducation.field_of_studyProportional hazards modelbusiness.industryMortality rateIncidence (epidemiology)MelanomaPopulationDermatologymedicine.diseaseNodular melanomaSurgeryBreslow ThicknessInfectious DiseasesInternal medicineCutaneous melanomamedicineeducationbusinessJournal of the European Academy of Dermatology and Venereology
researchProduct

The Assessment of Second Primary Cancers (SPCs) in a Series of Splenic Marginal Zone Lymphoma (SMZL) Patients

2006

The purpose of this study is to estimate the risk of second primary cancer (SPC) in 129 consecutive patients with splenic marginal zone lymphoma (SMZL) diagnosed in three Italian haematological centres. The person-years method deriving as a sum of products of age- and sex- specific rates and of the corresponding time at risk was used. The SPC Standardized Incidence Ratio (SIR) was 2.03 with a 95% confidence interval: [1.05, 3.56] (p < 0.05) and the corresponding Absolute Excess Risk (AER) was 145.8 (per 10000 SMZL patients per year). Our findings evidence a high frequency of additional cancers in patients with SMZL and suggest that the incidence rate of SPCs is significantly different from …

Oncologymedicine.medical_specialtyeducation.field_of_studySeries (stratigraphy)business.industryPopulationAbsolute risk reductionmedicine.diseaseSecond Primary CancersConfidence intervalStandardized mortality ratioTime at riskInternal medicinemedicineSplenic marginal zone lymphomaeducationbusiness
researchProduct

Insulin withdrawal in diabetic kidney disease : What are we waiting for?

2021

The prevalence of type 2 diabetes mellitus worldwide stands at nearly 9.3% and it is estimated that 20–40% of these patients will develop diabetic kidney disease (DKD). DKD is the leading cause of chronic kidney disease (CKD), and these patients often present high morbidity and mortality rates, particularly in those patients with poorly controlled risk factors. Furthermore, many are overweight or obese, due primarily to insulin compensation resulting from insulin resistance. In the last decade, treatment with sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) have been shown to be beneficial in renal and cardiovascular targets; however…

Opinionmedicine.medical_specialtyinsulinHealth Toxicology and Mutagenesismedicine.medical_treatmentRenal function030209 endocrinology & metabolism030204 cardiovascular system & hematologyOverweight03 medical and health sciences0302 clinical medicineInsulin resistancecardiovascular diseaseInternal medicinemedicineHumansHypoglycemic AgentsInsulinDiabetic NephropathiesSGLT2iDiabetic kidney diseaseSodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsDiabetisbusiness.industryInsulinMortality ratePublic Health Environmental and Occupational HealthRType 2 Diabetes Mellitusmedicine.diseaseRepaglinideCardiovascular diseaseGLP-1RAdiabetic kidney diseaseCor MalaltiesDiabetes Mellitus Type 2Medicinemedicine.symptombusinessKidney diseasemedicine.drug
researchProduct